Information for patients
We are moving from promise to practice in the clinic.View our clinical trials
ASG-15ME is an antibody-drug conjugate (ADC) targeting SLITRK6. SLITRK6 is found in urothelial cancer and other cancers, including lung, breast and glioblastoma. The antibody is attached to a potent, synthetic cytotoxic (cell-killing) agent, monomethyl auristatin E (MMAE), via an enzyme-cleavable linker using Seattle Genetics' proprietary technology.
The linker system is designed to be stable in the bloodstream and release the cytotoxic agent once inside target cancer cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects patients may experience during treatment with traditional chemotherapy while enhancing the antitumor activity.
We are co-developing ASG-15ME under an agreement with Astellas. ASG-15ME is in a phase 1 clinical trial to evaluate the safety and antitumor activity of escalating doses of ASG-15ME in patients with urothelial cancer.